Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00310648 | Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years) | PHASE3 | COMPLETED | 600 | — | — | Jan 1, 2006 | - | Sep 14, 2006 | 1 | China |
| NCT00408395 | Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children | PHASE2 | COMPLETED | 281 | — | — | Nov 1, 2006 | Aug 1, 2007 | Dec 1, 2016 | 1 | Finland |
| NCT00316628 | Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over. | PHASE2 | COMPLETED | 50 | — | — | Jun 1, 2005 | - | Sep 14, 2006 | 2 | Italy |
| Arm | Type | Description |
|---|---|---|
| 1: Trivalent Seasonal Influenza Vaccine | EXPERIMENTAL | - |
| 2: Adjuvanted Trivalent Seasonal Influenza Vaccine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Influenza vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Subjects 60 years of age or older, mentally competent, willing and able to give the written informed consent prior to study entry Exclusion Criteria: * Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic disease or complicated diabetes mellitus...